One & One Green Technologies stock soars 100% after IPO debut
Investing.com - H.C. Wainwright has reiterated its Buy rating and $100.00 price target on Immunocore Holdings (NASDAQ:IMCR), currently trading at $34.42, following a meeting with company management at the firm’s 27th Annual Global Investment Conference on September 8. According to InvestingPro data, analysts maintain a strong bullish consensus on the stock, which appears undervalued based on Fair Value analysis.
The research firm noted that Immunocore’s management team, including CFO and head of Corporate Development Travis Coy, expressed optimism about KIMMTRAK revenue growth observed during the first half of 2025.
According to H.C. Wainwright, this revenue growth is supporting Immunocore’s pipeline expansion, particularly in autoimmune programs.
The company reported a cash position of $883 million as of June 30, 2025, which H.C. Wainwright believes provides strong financial backing for its clinical development activities.
H.C. Wainwright cited Immunocore’s maturing clinical pipeline across multiple therapeutic areas as a key factor in its positive outlook for the company’s continued growth prospects.
In other recent news, Immunocore Holdings reported its second-quarter earnings for 2025, surpassing revenue expectations with sales of $98 million compared to the forecasted $92.04 million. This revenue beat represents a 6.48% surprise, although the company’s earnings per share fell short, reporting -$0.20 against an anticipated -$0.18. Additionally, Jefferies assumed coverage of Immunocore Holdings with a Buy rating and set a price target of $48. Jefferies highlighted the company’s off-the-shelf T-cell receptor platform, which addresses a range of diseases such as cancers, infections, and autoimmune conditions. These recent developments provide investors with insights into Immunocore’s financial performance and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.